Novartis AG
Formylated N-heterocyclic derivatives as FGFR4 inhibitors

Abstract:

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; ##STR00001## a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.